Papillary Carcinoma — Trials

Papillary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

206 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 51
Recruiting: 20
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06792552	A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors	recruiting	Phase 1	738	NextCure, Inc.INDUSTRY	2	Aug 17, 2026	clinicaltrials
NCT05665361	Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	recruiting	Phase 1 / Phase 2	100	National Cancer Institute (NCI)NIH	1	Jul 29, 2026	clinicaltrials